C. Chodkiewicz

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

J. Maurel, H. Wasan, J. Spano, 2009, British Journal of Cancer.

Leptomeningeal metastases from solid malignancy: a review

K. Hoang-Xuan, M. Sanson, S. Taillibert, 2005, Journal of Neuro-Oncology.

Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy: An update

J. Homsi, P. Munster, A. Daud, 2006 .

Gliomatosis Cerebri: A Review of 296 Cases from the ANOCEF Database and the Literature

M. Sanson, S. Taillibert, F. Laigle-Donadey, 2005, Journal of Neuro-Oncology.

A case of primary squamous cell colon cancer

C. Garrett, D. Landau, C. Chodkiewicz, 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Community oncologists’ perceptions and utilization of large-panel genomic tumor testing

Karen E. Rasmussen, J. Roberts, M. Hall, 2021, BMC Cancer.

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Suzanne F. Jones, F. Gao, R. Govindan, 2007, Clinical Cancer Research.

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

P. Bycott, J. Maurel, H. Wasan, 2008, The Lancet.

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor

A. Pavlick, H. Hochster, F. Muggia, 2004, Anti-cancer drugs.

Current progress in targeted therapy for colorectal cancer.

C. Vigil, C. Chodkiewicz, J. Ortega, 2010, Cancer control : journal of the Moffitt Cancer Center.